Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 11, Issue 1, 2017, Pages 276-284

  Liu, Meimei ^a   Li, Yan ^b   Yang, Shang Tian ^a  

^a The Ohio State University   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

amniotic fluid derived stem cell; mesenchymal stem cells; naringin; osteogenic differentiation; proliferation; signalling pathways

Indexed keywords

BONE; CELL CULTURE; CELL SIGNALING; COPYRIGHTS; FLAVONOIDS; MEDICINE; PHOSPHATASES; PLANTS (BOTANY); TRANSCRIPTION;

AMNIOTIC FLUID; AMNIOTIC FLUID-DERIVED STEM CELL; CELL-BE; CELL/B.E; MESENCHYMAL STEM CELL; NARINGIN; OSTEOGENIC DIFFERENTIATION; PROLIFERATION; SIGNALLING PATHWAYS; STEM-CELL;

STEM CELLS;

ALKALINE PHOSPHATASE; AURANTIIN; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; CALCIUM; WNT PROTEIN; BMP4 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 4; FLAVANONE DERIVATIVE; HERBACEOUS AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; TNFSF11 PROTEIN, HUMAN;

AMNIOTIC FLUID STEM CELL; ARTICLE; BETA CATENIN GENE; BMP4 GENE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; COLLAGEN I GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN D1 GENE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MARKER GENE; OPG GENE; OPN GENE; OSTEOBLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RANKL GENE; RUNX2 GENE; UPREGULATION; WNT SIGNALING PATHWAY; AMNION FLUID; BONE; BONE DEVELOPMENT; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; STEM CELL; WNT SIGNALING;

ALKALINE PHOSPHATASE; AMNIOTIC FLUID; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 4; CALCIUM; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DRUGS, CHINESE HERBAL; FLAVANONES; HUMANS; OSTEOGENESIS; OSTEOPONTIN; OSTEOPROTEGERIN; RANK LIGAND; STEM CELLS; WNT SIGNALING PATHWAY;

EID: 84902039887     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1911     Document Type: Article

References (55)

1. AAOS. 2008; Burden of Musculoskeletal Diseases in the United States: Prevalence, Societal and Economic Cost. American Academy of Orthopaedic Surgeons: Rosemont, IL, USA.
2. Arum SM. 2008; New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes 15: 508–513.
3. Babij P, Zhao WG, Small C et al. 2003; High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18: 960–974.
4. Bain G, Muller T, Wang X et al. 2003; Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2-mediated signal transduction. Biochem Biophys Res Commun 301: 84–81.
5. Bandyopadhyay A, Yadav PS, Prashar P. 2013; BMP signaling in development and diseases: a pharmacological perspective. Biochem Pharmacol 85: 857–j864.
6. Boyce BF, Xing LP. 2008; Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139–146.
7. Boyden LM, Mao JH, Belsky J et al. 2002; High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513–1521.
8. Chen KY, Lin KC, Chen YS et al. 2013; A novel porous gelatin composite containing naringin for bone repair. Evid Based Compl Alternat Med 28394: 1.
9. Day TF, Guo X, Garrett-Beal L et al. 2005; Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8: 739–750.
10. De Coppi P, Bartsch G Jr, Siddiqui MM et al. 2007; Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25: 100–106.
11. Egermann M, Goldhahn J, Schneider E. 2005; Animal models for fracture treatment in osteoporosis. Osteoporos Int 16: S129–138.
12. Gaur T, Lengner CJ, Hovhannisyan H et al. 2005; Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280: 33132–33140.
13. Guan X, Delo DM, Atala A et al. 2011; In vitro cardiomyogenic potential of human amniotic fluid stem cells. J Tissue Eng Regen Med 5: 220–228.
14. Hadjidakis DJ, Androulakis II. 2006; Bone remodeling. Ann NY Acad Sci 1092: 385–396.
15. Hamidouche Z, Hay E, Vaudin P et al. 2008; FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/β-catenin signaling-dependent Runx2 expression. FASEB J 22: 3813–3822.
16. Hu H, Hilton MJ, Tu X et al. 2005; Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132: 49–50.
17. Huang W, Yang S, Shao J et al. 2007; Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 12: 3068–3092.
18. Jeong JC, Lee JW, Yoon CH et al. 2005; Stimulative effects of Rhizoma drynariae extracts on the proliferation and differentiation of osteoblastic MC3T3-E1 cells. J Ethnopharmacol 96: 489–495.
19. Jiao L, Cao DP, Qin LP et al. 2009; Antiosteoporotic activity of phenolic compounds from Curculigo orchioides. Phytomedicine 16: 874–881.
20. Komori T. 2011; Signaling networks in RUNX2-dependent bone development. J Cell Biochem 112: 750–755.
21. Krieger N, Lowy I, Aronowitz R et al. 2005; Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Commun Health 59: 740–748.
22. Lee MH, Kim YJ, Kim HJ et al. 2003; BMP-2-induced Runx2 expression is mediated by Dlx5, and TGFβ1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278: 34387–34394.
23. Li D, Isherwood S, Motz A et al. 2013a; Cell-based screening of traditional Chinese medicines for proliferation enhancers of mouse embryonic stem cells. Biotechnol Prog 29: 738–744.
24. Li D, Zang R, Yang ST et al. 2013b; Cell-based high-throughput proliferation and cytotoxicity assays for screening traditional Chinese herbal medicines. Proc Biochem 48: 517–524.
25. Li N, Jiang Y, Wooley PH et al. 2013c; Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. J Orthop Sci 18: 478–485.
26. Lian JB, Stein GS, Javed A et al. 2006; Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 7: 1–6.
27. Licata AA. 2005; Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39: 668–677.
28. Liu M, Li Y, Yang ST. 2014a; Curculigoside improves osteogenesis of human amniotic fluid derived stem cells. Stem Cells Dev 23: 146–154.
29. Liu M, Li Y, Yang ST. 2014b; Expansion of human amniotic fluid stem cells in three-dimensional fibrous scaffolds in stirred bioreactors. Biochem Eng J 82: 71–80.
30. Liu Y, Wu J, Zhu Y et al. 2014c; Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med 14: 13–14.
31. Ma X, Zhang S, Zhou J et al. 2012; Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo. J Tissue Eng Regen Med 6: 598–513.
32. Mathews S, Bhonde R, Gupta PK et al. 2012; Extracellular matrix protein mediated regulation of the osteoblast differentiation of bone marrow derived human mesenchymal stem cells. Differentiation 84: 185–192.
33. Marshall JK. 2002; The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Safety 1: 71–78.
34. NIH. 2000; Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement Online 17: 1–6.
35. Nishio Y, Dong YF, Paris M et al. 2006; Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene 372: 62–70.
36. Orsini LS, Rousculp MD, Long SR et al. 2005; Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16: 359–371.
37. Pang WY, Wang XL, Mok SK et al. 2010; Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br J Pharmacol 159: 1693–1703.
38. Peng Y, Kang Q, Cheng H et al. 2003; Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem 90: 1149–1165.
39. Rawadi G, Vayssiere B, Dunn F et al. 2003; BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18: 1842–1853.
40. Reginster JY, Burlet N. 2006; Osteoporosis: a still increasing prevalence. Bone 38: 4.
41. Rodrigues MT, Lee SJ, Gomes ME et al. 2012; Amniotic fluid-derived stem cells as a cell source for bone tissue engineering. Tissue Eng A 18: 2518–2527.
42. Rossini M, Gatti D, Adami S. 2013; Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93: 121–132.
43. Rotella DP. 2002; Osteoporosis: challenges and new opportunities for therapy. Curr Opin Drug Discov Dev 5: 477–486.
44. Roubelakis MG, Pappa KI, Bitsika V et al. 2007; Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 16: 931–952.
45. Ryoo HM, Lee MH, Kim YJ. 2006; Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene 366: 51–57.
46. Shtutman M, Zhurinsky J, Simcha I et al. 1999; The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96: 5522–5527.
47. Teede HJ. 2003; Hormone replacement therapy, cardiovascular and cerebrovascular disease. Best Pract Res Clin Endoc Metab 17: 73–80.
48. Trohatou O, Anagnou NP, Roubelakis MG. 2013; Human amniotic fluid stem cells as an attractive tool for clinical applications. Curr Stem Cell Res Ther 8: 125–132.
49. Westendorf JJ, Kahler RA, Schroeder TM. 2004; Wnt signaling in osteoblasts and bone diseases. Gene 341: 19–29.
50. Wong R, Rabie B, Bendeus M et al. 2007; The effects of Rhizoma curculiginis and Rhizoma drynariae extracts on bones. Chin Med 2: 13.
51. Yeh YC, Wei HJ, Lee WY et al. 2010; Cellular cardiomyoplasty with human amniotic fluid stem cells: in vitro and in vivo studies. Tissue Eng A 16: 1925–1936.
52. Zhai YK, Niu YB, Pan YL et al. 2013; Effects of naringin on proliferation, differentiation and maturation of rat calvarial osteoblasts in vitro. Zhongguo Zhong Yao Za Zhi 38: 105–111.
53. Zhang JF, Li G, Chan CY et al. 2010; Flavonoids of Herba epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/β-catenin signaling pathway. Mol Cell Endocrinol 314: 70–74.
54. Zhang JF, Li G, Meng CL et al. 2009a. Total flavonoids of Herba epimedii improves osteogenesis and inhibits osteoclastogenesis of human mesenchymal stem cells. Phytomedicine 16: 521–529.
55. Zhang P, Dai KR, Yan SG et al. 2009b; Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cell. Eur J Pharmacol 607: 1.